Testosterone Replacement or Supplementation Therapy
UnitedHealthcare Commercial Medical Benefit Drug Policy Testosterone Replacement or Supplementation Therapy Policy Number: 2022D0076E. Effective Date: January 1, 2022 Instructions for Use Table of Contents Page Community Plan Policy Coverage Rationale ........................................ ............................... 1 Testosterone Replacement or Supplementation Applicable Codes ........................................ .................................. 3 Therapy 6. Benefit Considerations ........................................ .......................... 6. Clinical Evidence ........................................ ................................... 7. Food and Drug Administration ........................................ ..... 7. References.
Aromatase inhibitor (e.g., Arimidex [anastrozole], Femara [letrozole], Aromasin [exemestane]) and . o Dosing is in accordance with the United States Food and Drug Administration approved labeling; and o Initial authorization will be for no more than 12 months.
Download Testosterone Replacement or Supplementation Therapy
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: